- Home
- FIVE vs NUVL Comparison
FIVE vs NUVL Comparison
Compare FIVE & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- NUVL
- Stock Information
- Founded
- FIVE 2002
- NUVL 2017
- Country
- FIVE United States
- NUVL United States
- Employees
- FIVE N/A
- NUVL N/A
- Industry
- FIVE Department/Specialty Retail Stores
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- FIVE Consumer Discretionary
- NUVL Health Care
- Exchange
- FIVE Nasdaq
- NUVL Nasdaq
- Market Cap
- FIVE 7.1B
- NUVL 5.8B
- IPO Year
- FIVE 2012
- NUVL 2021
- Fundamental
- Price
- FIVE $153.40
- NUVL $80.89
- Analyst Decision
- FIVE Buy
- NUVL Strong Buy
- Analyst Count
- FIVE 17
- NUVL 11
- Target Price
- FIVE $146.13
- NUVL $120.91
- AVG Volume (30 Days)
- FIVE 1.4M
- NUVL 431.2K
- Earning Date
- FIVE 08-27-2025
- NUVL 08-07-2025
- Dividend Yield
- FIVE N/A
- NUVL N/A
- EPS Growth
- FIVE N/A
- NUVL N/A
- EPS
- FIVE 4.95
- NUVL N/A
- Revenue
- FIVE $4,231,969,000.00
- NUVL N/A
- Revenue This Year
- FIVE $16.91
- NUVL N/A
- Revenue Next Year
- FIVE $9.55
- NUVL N/A
- P/E Ratio
- FIVE $30.88
- NUVL N/A
- Revenue Growth
- FIVE 13.88
- NUVL N/A
- 52 Week Low
- FIVE $52.38
- NUVL $55.54
- 52 Week High
- FIVE $155.34
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- FIVE 68.13
- NUVL 61.76
- Support Level
- FIVE $141.81
- NUVL $73.28
- Resistance Level
- FIVE $154.30
- NUVL $81.10
- Average True Range (ATR)
- FIVE 5.01
- NUVL 2.51
- MACD
- FIVE 1.08
- NUVL 0.77
- Stochastic Oscillator
- FIVE 90.51
- NUVL 83.27
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.